Role of RUNX Family Transcription Factors in DNA Damage Response

[1]  W. Gu,et al.  p53 modifications: exquisite decorations of the powerful guardian , 2019, Journal of molecular cell biology.

[2]  A. D’Andrea,et al.  The Fanconi Anemia Pathway in Cancer. , 2019, Annual review of cancer biology.

[3]  J. Hyun,et al.  RUNX3 regulates cell cycle-dependent chromatin dynamics by functioning as a pioneer factor of the restriction-point , 2018, Nature Communications.

[4]  T. Tan,et al.  RUNX Poly(ADP-Ribosyl)ation and BLM Interaction Facilitate the Fanconi Anemia Pathway of DNA Repair. , 2018, Cell reports.

[5]  Y. M. Lee,et al.  Emerging role of RUNX3 in the regulation of tumor microenvironment , 2018, BMB reports.

[6]  N. Speck,et al.  RUNX1 Mutations in Inherited and Sporadic Leukemia , 2017, Front. Cell Dev. Biol..

[7]  J. A. Pulikkan,et al.  RUNX1 is required for oncogenic Myb and Myc enhancer activity in T-cell acute lymphoblastic leukemia. , 2017, Blood.

[8]  A. D’Andrea,et al.  Fanconi anemia pathway , 2017, Current Biology.

[9]  Y. Ito,et al.  Runx3 plays a critical role in restriction-point and defense against cellular transformation , 2017, Oncogene.

[10]  Li-xian Chang,et al.  Pathogenesis of ETV6/RUNX1-positive childhood acute lymphoblastic leukemia and mechanisms underlying its relapse , 2017, Oncotarget.

[11]  M. Fischer,et al.  Census and evaluation of p53 target genes , 2017, Oncogene.

[12]  Xiaoping Zhou,et al.  Negative auto-regulators trap p53 in their web. , 2017, Journal of molecular cell biology.

[13]  Y. M. Lee,et al.  Roles of RUNX in Hypoxia-Induced Responses and Angiogenesis. , 2017, Advances in experimental medicine and biology.

[14]  T. Ozaki,et al.  Depletion of pro-oncogenic RUNX2 enhances gemcitabine (GEM) sensitivity of p53-mutated pancreatic cancer Panc-1 cells through the induction of pro-apoptotic TAp63 , 2016, Oncotarget.

[15]  M. Cohn,et al.  Cellular response to DNA interstrand crosslinks: the Fanconi anemia pathway , 2016, Cellular and Molecular Life Sciences.

[16]  Yunlong He,et al.  A RUNX2-Mediated Epigenetic Regulation of the Survival of p53 Defective Cancer Cells , 2016, PLoS genetics.

[17]  F. Rosselli,et al.  Impaired TIP60-mediated H4K16 acetylation accounts for the aberrant chromatin accumulation of 53BP1 and RAP80 in Fanconi anemia pathway-deficient cells , 2015, Nucleic acids research.

[18]  Salam A. Assi,et al.  The leukemia-associated RUNX1/ETO oncoprotein confers a mutator phenotype , 2015, Leukemia.

[19]  Amanda J. Wilson,et al.  Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors , 2015, Nature Network Boston.

[20]  L. Donehower,et al.  Loss of Runx2 sensitises osteosarcoma to chemotherapy-induced apoptosis , 2015, British Journal of Cancer.

[21]  J. Błasiak,et al.  Role of RUNX2 in Breast Carcinogenesis , 2015, International journal of molecular sciences.

[22]  M. Nakamura,et al.  Silencing of RUNX2 enhances gemcitabine sensitivity of p53-deficient human pancreatic cancer AsPC-1 cells through the stimulation of TAp63-mediated cell death , 2015, Cell Death and Disease.

[23]  Long Gao,et al.  Runx1 Deficiency Decreases Ribosome Biogenesis and Confers Stress Resistance to Hematopoietic Stem and Progenitor Cells. , 2015, Cell stem cell.

[24]  S. Gabriel,et al.  Deficiency of UBE2T, the E2 Ubiquitin Ligase Necessary for FANCD2 and FANCI Ubiquitination, Causes FA-T Subtype of Fanconi Anemia. , 2015, Cell reports.

[25]  D. Bluteau,et al.  Level of RUNX1 activity is critical for leukemic predisposition but not for thrombocytopenia. , 2015, Blood.

[26]  Yoshiaki Ito,et al.  The RUNX family: developmental regulators in cancer , 2015, Nature Reviews Cancer.

[27]  S. M. Reed,et al.  p53 Acetylation: Regulation and Consequences , 2014, Cancers.

[28]  L. Godley.  Inherited predisposition to acute myeloid leukemia. , 2014, Seminars in hematology.

[29]  T. Tan,et al.  Disruption of Runx1 and Runx3 leads to bone marrow failure and leukemia predisposition due to transcriptional and DNA repair defects. , 2014, Cell reports.

[30]  F. Rosselli,et al.  Fanca deficiency reduces A/T transitions in somatic hypermutation and alters class switch recombination junctions in mouse B cells , 2014, The Journal of experimental medicine.

[31]  Meng Wang,et al.  Role of RUNX3 in Suppressing Metastasis and Angiogenesis of Human Prostate Cancer , 2014, PloS one.

[32]  A. Nakagawara,et al.  RUNX Family Participates in the Regulation of p53-Dependent DNA Damage Response , 2013, International journal of genomics.

[33]  L. Zou,et al.  DNA damage sensing by the ATM and ATR kinases. , 2013, Cold Spring Harbor perspectives in biology.

[34]  Manikandan Paramasivam,et al.  ATR-dependent phosphorylation of FANCM at serine 1045 is essential for FANCM functions. , 2013, Cancer research.

[35]  A. Nakagawara,et al.  Runt-related transcription factor 2 (RUNX2) inhibits p53-dependent apoptosis through the collaboration with HDAC6 in response to DNA damage , 2013, Cell Death and Disease.

[36]  A. Nakagawara,et al.  Runt-related Transcription Factor 1 (RUNX1) Stimulates Tumor Suppressor p53 Protein in Response to DNA Damage through Complex Formation and Acetylation* , 2012, The Journal of Biological Chemistry.

[37]  K. J. Patel,et al.  The Fanconi Anaemia Components UBE2T and FANCM Are Functionally Linked to Nucleotide Excision Repair , 2012, PloS one.

[38]  I. Matsumura,et al.  C-terminal mutation of RUNX1 attenuates the DNA-damage repair response in hematopoietic stem cells , 2012, Leukemia.

[39]  H. Harada,et al.  Molecular mechanisms that produce secondary MDS/AML by RUNX1/AML1 point mutations , 2011, Journal of cellular biochemistry.

[40]  G. Stein,et al.  The Role of RUNX2 in Osteosarcoma Oncogenesis , 2010, Sarcoma.

[41]  N. Speck,et al.  RUNX1 mutations in clonal myeloid disorders: from conventional cytogenetics to next generation sequencing, a story 40 years in the making. , 2011, Critical reviews in oncogenesis.

[42]  M. Weitzman,et al.  The MRN complex in double‐strand break repair and telomere maintenance , 2010, FEBS letters.

[43]  A. Jones,et al.  Transcription factor mutations in myelodysplastic/myeloproliferative neoplasms , 2010, Haematologica.

[44]  G. Kupfer,et al.  Several tetratricopeptide repeat (TPR) motifs of FANCG are required for assembly of the BRCA2/D1-D2-G-X3 complex, FANCD2 monoubiquitylation and phleomycin resistance. , 2010, Mutation research.

[45]  J. Lees,et al.  Rb regulates fate choice and lineage commitment in vivo , 2010, Nature.

[46]  Yoshiaki Ito,et al.  RUNX3 is multifunctional in carcinogenesis of multiple solid tumors , 2010, Oncogene.

[47]  R. Hills,et al.  OGG1 is a novel prognostic indicator in acute myeloid leukaemia , 2010, Oncogene.

[48]  A. Nakagawara,et al.  RUNX3 Modulates DNA Damage-mediated Phosphorylation of Tumor Suppressor p53 at Ser-15 and Acts as a Co-activator for p53* , 2010, The Journal of Biological Chemistry.

[49]  Jiandong Chen,et al.  Mechanism of p53 stabilization by ATM after DNA damage , 2010, Cell cycle.

[50]  N. Reich,et al.  Stress-mediated nuclear stabilization of p53 is regulated by ubiquitination and importin-α3 binding , 2010, Cell Death and Differentiation.

[51]  G. Stein,et al.  Runx2 Association with Progression of Prostate Cancer in Patients: Mechanisms Mediating Bone Osteolysis and Osteoblastic Metastatic Lesions , 2009, Oncogene.

[52]  H. Bengtsson,et al.  Novel RUNX1 mutations in familial platelet disorder with enhanced risk for acute myeloid leukemia: clues for improved identification of the FPD/AML syndrome , 2010, Leukemia.

[53]  A. D’Andrea,et al.  How the fanconi anemia pathway guards the genome. , 2009, Annual review of genetics.

[54]  G. Stein,et al.  Runt-related transcription factor RUNX3 is a target of MDM2-mediated ubiquitination. , 2009, Cancer research.

[55]  D. Levanon,et al.  Runx3-deficient mouse strains circa 2008: resemblance and dissimilarity. , 2009, Blood cells, molecules & diseases.

[56]  F. Rosselli,et al.  The FANC pathway and BLM collaborate during mitosis to prevent micro-nucleation and chromosome abnormalities , 2009, Nature Cell Biology.

[57]  I. Hickson,et al.  Replication stress induces sister-chromatid bridging at fragile site loci in mitosis , 2009, Nature Cell Biology.

[58]  D. Liang,et al.  RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation , 2009, Leukemia.

[59]  B. Leber,et al.  Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy. , 2008, Blood.

[60]  S. K. Zaidi,et al.  Runx2 transcriptional activation of Indian Hedgehog and a downstream bone metastatic pathway in breast cancer cells. , 2008, Cancer research.

[61]  P. Andreassen,et al.  p53 signaling in response to increased DNA damage sensitizes AML1-ETO cells to stress-induced death. , 2007, Blood.

[62]  Weidong Wang.  Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins , 2007, Nature Reviews Genetics.

[63]  Y. Zou,et al.  Functions of human replication protein A (RPA): From DNA replication to DNA damage and stress responses , 2006, Journal of cellular physiology.

[64]  K. Blyth,et al.  Runx2 and MYC collaborate in lymphoma development by suppressing apoptotic and growth arrest pathways in vivo. , 2006, Cancer research.

[65]  Karen Blyth,et al.  The runx genes: gain or loss of function in cancer , 2005, Nature Reviews Cancer.

[66]  J. Mi,et al.  Phosphorylation of Fanconi Anemia (FA) Complementation Group G Protein, FANCG, at Serine 7 Is Important for Function of the FA Pathway* , 2004, Journal of Biological Chemistry.

[67]  J. Bushweller,et al.  CBFβ allosterically regulates the Runx1 Runt domain via a dynamic conformational equilibrium , 2004, Nature Structural &Molecular Biology.

[68]  E. Baxter,et al.  RUNX1 transformation of primary embryonic fibroblasts is revealed in the absence of p53 , 2004, Oncogene.

[69]  Motomi Osato.  Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia , 2004, Oncogene.

[70]  S. Bae,et al.  Tumor suppressor activity of RUNX3 , 2004, Oncogene.

[71]  A. Huvos,et al.  Frequent amplification and rearrangement of chromosomal bands 6p12‐p21 and 17p11.2 in osteosarcoma , 2004, Genes, chromosomes & cancer.

[72]  Natalia Meani,et al.  Acute myeloid leukemia fusion proteins deregulate genes involved in stem cell maintenance and DNA repair. , 2003, The Journal of clinical investigation.

[73]  C. Bishop,et al.  A novel ubiquitin ligase is deficient in Fanconi anemia , 2003, Nature Genetics.

[74]  Yanping Zhang,et al.  Nucleocytoplasmic Shuttling of p53 Is Essential for MDM2-Mediated Cytoplasmic Degradation but Not Ubiquitination , 2003, Molecular and Cellular Biology.

[75]  S. K. Zaidi,et al.  Runx2 (Cbfa1, AML-3) Interacts with Histone Deacetylase 6 and Represses the p21CIP1/WAF1 Promoter , 2002, Molecular and Cellular Biology.

[76]  D. Woods,et al.  C-Terminal Ubiquitination of p53 Contributes to Nuclear Export , 2001, Molecular and Cellular Biology.

[77]  R. Kanaar,et al.  Repair of DNA interstrand cross-links. , 2001, Mutation research.

[78]  P. McHugh,et al.  Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance. , 2001, The Lancet. Oncology.

[79]  R. Hay,et al.  Multiple C-Terminal Lysine Residues Target p53 for Ubiquitin-Proteasome-Mediated Degradation , 2000, Molecular and Cellular Biology.

[80]  Chaohong Sun,et al.  The Ig fold of the core binding factor alpha Runt domain is a member of a family of structurally and functionally related Ig-fold DNA-binding domains. , 1999, Structure.

[81]  John M. Maris,et al.  Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia , 1999, Nature Genetics.

[82]  K. Tanaka,et al.  TLE, the human homolog of groucho, interacts with AML1 and acts as a repressor of AML1-induced transactivation. , 1998, Biochemical and biophysical research communications.

[83]  M. Buchwald,et al.  Multiple inhibitory cytokines induce deregulated progenitor growth and apoptosis in hematopoietic cells from Fac-/- mice. , 1998, Blood.

[84]  S. Mundlos,et al.  Cbfa1, a Candidate Gene for Cleidocranial Dysplasia Syndrome, Is Essential for Osteoblast Differentiation and Bone Development , 1997, Cell.

[85]  Makoto Sato,et al.  Targeted Disruption of Cbfa1 Results in a Complete Lack of Bone Formation owing to Maturational Arrest of Osteoblasts , 1997, Cell.

[86]  D. Phillips,et al.  DNA adducts from chemotherapeutic agents. , 1996, Mutation research.

[87]  M. Marín‐Padilla,et al.  Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[88]  R. Braun,et al.  Germ cell defects and hematopoietic hypersensitivity to gamma-interferon in mice with a targeted disruption of the Fanconi anemia C gene. , 1996, Blood.

[89]  O. Myklebost,et al.  Comparative genomic hybridization analysis of human sarcomas: II. Identification of novel amplicons at 6p and 17p in osteosarcomas , 1995, Genes, chromosomes & cancer.

[90]  B. Vogelstein,et al.  Participation of p53 protein in the cellular response to DNA damage. , 1991, Cancer research.

[91]  H. Hoehn,et al.  Fanconi anemia mutation causes cellular susceptibility to ambient oxygen. , 1988, American journal of human genetics.